High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes
Aims To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes. Methods The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or co...
Gespeichert in:
| Veröffentlicht in: | Acta diabetologica 2021-05, Vol.58 (5), p.595-602 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 602 |
|---|---|
| container_issue | 5 |
| container_start_page | 595 |
| container_title | Acta diabetologica |
| container_volume | 58 |
| creator | Yang, Kun Wang, Haining Wei, Rui Xiao, Wenhua Tian, Qing Wang, Chen Yang, Jin Hong, Tianpei |
| description | Aims
To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes.
Methods
The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues. All participants received exenatide twice daily as an add-on therapy for 16 weeks. Serum FGF21 and other information at the baseline and end of follow-ups were obtained. Linear regression analysis was used to determine the correlations between baseline FGF21 levels and HbA1c reduction from baseline after the treatment.
Results
After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (
r
= 0.193,
P
= 0.008) and in subgroup of the participants receiving background metformin monotherapy (
r
= 0.231,
P
= 0.034). Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (
β
= − 0.16 [95% Cl − 0.31 to − 0.01],
P
|
| doi_str_mv | 10.1007/s00592-020-01660-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478595770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478595770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-a76babb3e88bd7c7f21f068e227da04fd8fb3f04c232639adf126687a529c23b3</originalsourceid><addsrcrecordid>eNp9kc1u1DAURi1ERac_L8ACWWLDxmBfx7GzRBXTVqrEhq4tx7meusrEwU4oU16elBSQWLCyZZ3v89U9hLwW_L3gXH8onKsGGAfOuKhrzh5fkI2oJDAFUr4kG95UnKkKmmNyUso95wK0NK_IsZSVAtWoDflxFXd3tHUF-zgg3V5uQdAev2FfqMtIXSnJRzdhRx_idEfHlDLd9bNPBVmfHjDHYUcxhOidP9AUKH7HwU2xQxoHOi43HKayhqfDiBRoF12LE5YzchRcX_D8-Twlt9tPXy6u2M3ny-uLjzfMS60m5nTduraVaEzbaa8DiMBrgwC6c7wKnQmtDLzyIKGWjeuCgLo22ilolrdWnpJ3a--Y09cZy2T3sXjsezdgmouFSptlGVrzBX37D3qf5jws01lQwmiljIGFgpXyOZWSMdgxx73LByu4fVJjVzV2UWN_qbGPS-jNc_Xc7rH7E_ntYgHkCpTxaamY__79n9qfsHmadQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2518755882</pqid></control><display><type>article</type><title>High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes</title><source>SpringerNature Journals</source><creator>Yang, Kun ; Wang, Haining ; Wei, Rui ; Xiao, Wenhua ; Tian, Qing ; Wang, Chen ; Yang, Jin ; Hong, Tianpei</creator><creatorcontrib>Yang, Kun ; Wang, Haining ; Wei, Rui ; Xiao, Wenhua ; Tian, Qing ; Wang, Chen ; Yang, Jin ; Hong, Tianpei</creatorcontrib><description>Aims
To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes.
Methods
The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues. All participants received exenatide twice daily as an add-on therapy for 16 weeks. Serum FGF21 and other information at the baseline and end of follow-ups were obtained. Linear regression analysis was used to determine the correlations between baseline FGF21 levels and HbA1c reduction from baseline after the treatment.
Results
After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (
r
= 0.193,
P
= 0.008) and in subgroup of the participants receiving background metformin monotherapy (
r
= 0.231,
P
= 0.034). Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (
β
= − 0.16 [95% Cl − 0.31 to − 0.01],
P
< 0.05) and in subgroup of the participants receiving background metformin monotherapy (
β
= − 0.23 [95% Cl − 0.43 to − 0.03],
P
< 0.05), after adjusting for the confounding factors, including age, sex, and baseline HbA1c levels.
Conclusions
The high baseline FGF21 levels are associated with poor glycemic responses to exenatide in patients with type 2 diabetes. Therefore, FGF21 could be used as a biomarker for predicting the efficacy of exenatide treatment.
Trial registration
ChiCTR-IPR-15006558, date registered May 27, 2015.</description><identifier>ISSN: 0940-5429</identifier><identifier>EISSN: 1432-5233</identifier><identifier>DOI: 10.1007/s00592-020-01660-z</identifier><identifier>PMID: 33452595</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Antidiabetics ; ChiCTR-IPR ; ChiCTR-IPR-15006558 ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Fibroblast growth factors ; Insulin ; Internal Medicine ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metformin ; Original Article</subject><ispartof>Acta diabetologica, 2021-05, Vol.58 (5), p.595-602</ispartof><rights>Springer-Verlag Italia S.r.l., part of Springer Nature 2021</rights><rights>Springer-Verlag Italia S.r.l., part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-a76babb3e88bd7c7f21f068e227da04fd8fb3f04c232639adf126687a529c23b3</citedby><cites>FETCH-LOGICAL-c375t-a76babb3e88bd7c7f21f068e227da04fd8fb3f04c232639adf126687a529c23b3</cites><orcidid>0000-0001-6004-955X ; 0000-0002-5744-5129 ; 0000-0002-7012-4557 ; 0000-0002-8838-703X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00592-020-01660-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00592-020-01660-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33452595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Kun</creatorcontrib><creatorcontrib>Wang, Haining</creatorcontrib><creatorcontrib>Wei, Rui</creatorcontrib><creatorcontrib>Xiao, Wenhua</creatorcontrib><creatorcontrib>Tian, Qing</creatorcontrib><creatorcontrib>Wang, Chen</creatorcontrib><creatorcontrib>Yang, Jin</creatorcontrib><creatorcontrib>Hong, Tianpei</creatorcontrib><title>High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes</title><title>Acta diabetologica</title><addtitle>Acta Diabetol</addtitle><addtitle>Acta Diabetol</addtitle><description>Aims
To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes.
Methods
The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues. All participants received exenatide twice daily as an add-on therapy for 16 weeks. Serum FGF21 and other information at the baseline and end of follow-ups were obtained. Linear regression analysis was used to determine the correlations between baseline FGF21 levels and HbA1c reduction from baseline after the treatment.
Results
After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (
r
= 0.193,
P
= 0.008) and in subgroup of the participants receiving background metformin monotherapy (
r
= 0.231,
P
= 0.034). Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (
β
= − 0.16 [95% Cl − 0.31 to − 0.01],
P
< 0.05) and in subgroup of the participants receiving background metformin monotherapy (
β
= − 0.23 [95% Cl − 0.43 to − 0.03],
P
< 0.05), after adjusting for the confounding factors, including age, sex, and baseline HbA1c levels.
Conclusions
The high baseline FGF21 levels are associated with poor glycemic responses to exenatide in patients with type 2 diabetes. Therefore, FGF21 could be used as a biomarker for predicting the efficacy of exenatide treatment.
Trial registration
ChiCTR-IPR-15006558, date registered May 27, 2015.</description><subject>Antidiabetics</subject><subject>ChiCTR-IPR</subject><subject>ChiCTR-IPR-15006558</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Fibroblast growth factors</subject><subject>Insulin</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metformin</subject><subject>Original Article</subject><issn>0940-5429</issn><issn>1432-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAURi1ERac_L8ACWWLDxmBfx7GzRBXTVqrEhq4tx7meusrEwU4oU16elBSQWLCyZZ3v89U9hLwW_L3gXH8onKsGGAfOuKhrzh5fkI2oJDAFUr4kG95UnKkKmmNyUso95wK0NK_IsZSVAtWoDflxFXd3tHUF-zgg3V5uQdAev2FfqMtIXSnJRzdhRx_idEfHlDLd9bNPBVmfHjDHYUcxhOidP9AUKH7HwU2xQxoHOi43HKayhqfDiBRoF12LE5YzchRcX_D8-Twlt9tPXy6u2M3ny-uLjzfMS60m5nTduraVaEzbaa8DiMBrgwC6c7wKnQmtDLzyIKGWjeuCgLo22ilolrdWnpJ3a--Y09cZy2T3sXjsezdgmouFSptlGVrzBX37D3qf5jws01lQwmiljIGFgpXyOZWSMdgxx73LByu4fVJjVzV2UWN_qbGPS-jNc_Xc7rH7E_ntYgHkCpTxaamY__79n9qfsHmadQ</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Yang, Kun</creator><creator>Wang, Haining</creator><creator>Wei, Rui</creator><creator>Xiao, Wenhua</creator><creator>Tian, Qing</creator><creator>Wang, Chen</creator><creator>Yang, Jin</creator><creator>Hong, Tianpei</creator><general>Springer Milan</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6004-955X</orcidid><orcidid>https://orcid.org/0000-0002-5744-5129</orcidid><orcidid>https://orcid.org/0000-0002-7012-4557</orcidid><orcidid>https://orcid.org/0000-0002-8838-703X</orcidid></search><sort><creationdate>20210501</creationdate><title>High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes</title><author>Yang, Kun ; Wang, Haining ; Wei, Rui ; Xiao, Wenhua ; Tian, Qing ; Wang, Chen ; Yang, Jin ; Hong, Tianpei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-a76babb3e88bd7c7f21f068e227da04fd8fb3f04c232639adf126687a529c23b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antidiabetics</topic><topic>ChiCTR-IPR</topic><topic>ChiCTR-IPR-15006558</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Fibroblast growth factors</topic><topic>Insulin</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metformin</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Kun</creatorcontrib><creatorcontrib>Wang, Haining</creatorcontrib><creatorcontrib>Wei, Rui</creatorcontrib><creatorcontrib>Xiao, Wenhua</creatorcontrib><creatorcontrib>Tian, Qing</creatorcontrib><creatorcontrib>Wang, Chen</creatorcontrib><creatorcontrib>Yang, Jin</creatorcontrib><creatorcontrib>Hong, Tianpei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta diabetologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Kun</au><au>Wang, Haining</au><au>Wei, Rui</au><au>Xiao, Wenhua</au><au>Tian, Qing</au><au>Wang, Chen</au><au>Yang, Jin</au><au>Hong, Tianpei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes</atitle><jtitle>Acta diabetologica</jtitle><stitle>Acta Diabetol</stitle><addtitle>Acta Diabetol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>58</volume><issue>5</issue><spage>595</spage><epage>602</epage><pages>595-602</pages><issn>0940-5429</issn><eissn>1432-5233</eissn><abstract>Aims
To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes.
Methods
The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues. All participants received exenatide twice daily as an add-on therapy for 16 weeks. Serum FGF21 and other information at the baseline and end of follow-ups were obtained. Linear regression analysis was used to determine the correlations between baseline FGF21 levels and HbA1c reduction from baseline after the treatment.
Results
After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (
r
= 0.193,
P
= 0.008) and in subgroup of the participants receiving background metformin monotherapy (
r
= 0.231,
P
= 0.034). Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (
β
= − 0.16 [95% Cl − 0.31 to − 0.01],
P
< 0.05) and in subgroup of the participants receiving background metformin monotherapy (
β
= − 0.23 [95% Cl − 0.43 to − 0.03],
P
< 0.05), after adjusting for the confounding factors, including age, sex, and baseline HbA1c levels.
Conclusions
The high baseline FGF21 levels are associated with poor glycemic responses to exenatide in patients with type 2 diabetes. Therefore, FGF21 could be used as a biomarker for predicting the efficacy of exenatide treatment.
Trial registration
ChiCTR-IPR-15006558, date registered May 27, 2015.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>33452595</pmid><doi>10.1007/s00592-020-01660-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6004-955X</orcidid><orcidid>https://orcid.org/0000-0002-5744-5129</orcidid><orcidid>https://orcid.org/0000-0002-7012-4557</orcidid><orcidid>https://orcid.org/0000-0002-8838-703X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0940-5429 |
| ispartof | Acta diabetologica, 2021-05, Vol.58 (5), p.595-602 |
| issn | 0940-5429 1432-5233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2478595770 |
| source | SpringerNature Journals |
| subjects | Antidiabetics ChiCTR-IPR ChiCTR-IPR-15006558 Diabetes Diabetes mellitus (non-insulin dependent) Fibroblast growth factors Insulin Internal Medicine Medicine Medicine & Public Health Metabolic Diseases Metformin Original Article |
| title | High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A37%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20baseline%20FGF21%20levels%20are%20associated%20with%20poor%20glucose-lowering%20efficacy%20of%20exenatide%20in%20patients%20with%20type%202%20diabetes&rft.jtitle=Acta%20diabetologica&rft.au=Yang,%20Kun&rft.date=2021-05-01&rft.volume=58&rft.issue=5&rft.spage=595&rft.epage=602&rft.pages=595-602&rft.issn=0940-5429&rft.eissn=1432-5233&rft_id=info:doi/10.1007/s00592-020-01660-z&rft_dat=%3Cproquest_cross%3E2478595770%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2518755882&rft_id=info:pmid/33452595&rfr_iscdi=true |